A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children
- PMID: 10381536
A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children
Abstract
Genetic modification of hematopoietic stem cells with genes that inhibit replication of human immunodeficiency virus-1 (HIV-1) could lead to development of T lymphocytes and monocytic cells resistant to HIV-1 infection after transplantation. We performed a clinical trial to evaluate the safety and feasibility of this procedure, using bone marrow from four HIV-1-infected pediatric subjects (ages 8 to 17 years). We obtained bone marrow, isolated CD34(+) cells, performed in vitro transduction with a retroviral vector carrying a rev-responsive element (RRE) decoy gene, and reinfused the cells into these subjects with no evidence of adverse effects. The levels of gene-containing leukocytes in peripheral blood samples in the 1 year after gene transfer/cell infusion have been extremely low. These observations support the potential of performing gene therapy for HIV-1 using hematopoietic cells, but emphasize the need for improved gene transfer techniques.
Similar articles
-
Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture.J Virol. 1996 Jul;70(7):4352-60. doi: 10.1128/JVI.70.7.4352-4360.1996. J Virol. 1996. PMID: 8676458 Free PMC article.
-
Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes.Blood. 1997 Apr 1;89(7):2259-67. Blood. 1997. PMID: 9116267
-
Gene therapy for pediatric AIDS.Ann N Y Acad Sci. 2000 Nov;918:318-29. doi: 10.1111/j.1749-6632.2000.tb05501.x. Ann N Y Acad Sci. 2000. PMID: 11131719 Review.
-
Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins.Hum Gene Ther. 1996 Jun 20;7(10):1281-306. doi: 10.1089/hum.1996.7.10-1281. Hum Gene Ther. 1996. PMID: 8793552 Clinical Trial. No abstract available.
-
Stem cell directed gene therapy.Front Biosci. 1999 May 1;4:e26-33. doi: 10.2741/engel. Front Biosci. 1999. PMID: 10228093 Review.
Cited by
-
Therapeutic applications of DNA and RNA aptamers.Oligonucleotides. 2009 Sep;19(3):209-22. doi: 10.1089/oli.2009.0199. Oligonucleotides. 2009. PMID: 19653880 Free PMC article. Review.
-
Efficacy, accumulation, and transcriptional profile of anti-HIV shRNAs expressed from human U6, 7SK, and H1 promoters.Mol Ther Nucleic Acids. 2021 Jan 1;23:1020-1034. doi: 10.1016/j.omtn.2020.12.022. eCollection 2021 Mar 5. Mol Ther Nucleic Acids. 2021. PMID: 33614248 Free PMC article.
-
Aptamers for Viral Detection and Inhibition.ACS Infect Dis. 2022 Apr 8;8(4):667-692. doi: 10.1021/acsinfecdis.1c00546. Epub 2022 Feb 27. ACS Infect Dis. 2022. PMID: 35220716 Free PMC article. Review.
-
RNA interference against viruses: strike and counterstrike.Nat Biotechnol. 2007 Dec;25(12):1435-43. doi: 10.1038/nbt1369. Nat Biotechnol. 2007. PMID: 18066040 Free PMC article. Review.
-
Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication.J Virol. 2002 Apr;76(8):4068-72. doi: 10.1128/jvi.76.8.4068-4072.2002. J Virol. 2002. PMID: 11907245 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
